Patents Assigned to Proximagen Limited
-
Publication number: 20190185467Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl(4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.Type: ApplicationFiled: July 21, 2016Publication date: June 20, 2019Applicant: PROXIMAGEN LIMITEDInventor: Lee PATIENT
-
Patent number: 10065954Abstract: Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 17, 2015Date of Patent: September 4, 2018Assignee: PROXIMAGEN LIMITEDInventors: Max Espensen, Lee Patient, Edward Savory
-
Publication number: 20180194763Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.Type: ApplicationFiled: March 5, 2018Publication date: July 12, 2018Applicant: PROXIMAGEN LIMITEDInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Publication number: 20180118744Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: December 29, 2017Publication date: May 3, 2018Applicant: PROXIMAGEN LIMITEDInventors: Edward SAVORY, Michael HIGGINBOTTOM, Kathryn OLIVER, Viet-Anh Anne HORGAN
-
Publication number: 20180111928Abstract: The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.Type: ApplicationFiled: April 22, 2016Publication date: April 26, 2018Applicant: PROXIMAGEN LIMITEDInventors: Edward SAVORY, Michael HIGGINBOTTOM
-
Patent number: 9951068Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.Type: GrantFiled: May 11, 2017Date of Patent: April 24, 2018Assignee: PROXIMAGEN LIMITEDInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Publication number: 20180104223Abstract: (3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.Type: ApplicationFiled: April 22, 2016Publication date: April 19, 2018Applicant: PROXIMAGEN LIMITEDInventors: Isabel GONZALEZ, Martyn PRITCHARD, Peter RICHARDSON
-
Publication number: 20180085357Abstract: A specific crystalline mesylate salt form of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate, and the use of the same in medicine.Type: ApplicationFiled: April 22, 2016Publication date: March 29, 2018Applicant: PROXIMAGEN LIMITEDInventor: Edward SAVORY
-
Publication number: 20180078563Abstract: The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers.Type: ApplicationFiled: April 1, 2016Publication date: March 22, 2018Applicant: PROXIMAGEN LIMITEDInventors: Peter RICHARDSON, Jacqueline Mary WALLING, Claudio FESTUCCIA
-
Patent number: 9890160Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: October 27, 2016Date of Patent: February 13, 2018Assignee: PROXIMAGEN LIMITEDInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 9676769Abstract: The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumor growth.Type: GrantFiled: March 13, 2014Date of Patent: June 13, 2017Assignee: Proximagen LimitedInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Patent number: 9580415Abstract: The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R1 and R2 are defined in the claims.Type: GrantFiled: March 13, 2014Date of Patent: February 28, 2017Assignee: Proximagen LimitedInventors: Lee Patient, David Evans, Iain Simpson, Allison Powell
-
Patent number: 9499510Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z1, Z2, and Z3, Q, R2, A, and R1 are as defined in the claims.Type: GrantFiled: July 3, 2013Date of Patent: November 22, 2016Assignee: Proximagen LimitedInventors: Edward Savory, Martyn Pritchard, Mike Ashwood
-
Patent number: 9493457Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: April 13, 2015Date of Patent: November 15, 2016Assignee: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20160318891Abstract: The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced) or cardiovascular diseases including myocardial infarction, coronary revascularization or angina. The compounds of the invention form a novel group of related prodrugs of formula (II), where Ar is a 3-chloro-4-fluorophenyl ring, a 3-chlorophenyl ring or a 4-fluorophenyl ring; and R is a hydrolysable group comprising an amino group or an acidic group.Type: ApplicationFiled: December 22, 2014Publication date: November 3, 2016Applicant: PROXIMAGEN LIMITEDInventors: Edward Savory, Martyn Pritchard, Michael Higginbottom, William John O'Neil
-
Patent number: 9428498Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.Type: GrantFiled: March 13, 2014Date of Patent: August 30, 2016Assignee: Proximagen LimitedInventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
-
Patent number: 9353086Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.Type: GrantFiled: October 13, 2011Date of Patent: May 31, 2016Assignee: Proximagen LimitedInventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
-
Patent number: 9227967Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.Type: GrantFiled: March 14, 2011Date of Patent: January 5, 2016Assignee: Proximagen LimitedInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Patent number: 9150574Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboType: GrantFiled: September 14, 2011Date of Patent: October 6, 2015Assignee: Proximagen LimitedInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Patent number: 9133178Abstract: Compounds are disclosed which modulate the ?7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims.Type: GrantFiled: October 26, 2011Date of Patent: September 15, 2015Assignee: Proximagen LimitedInventors: David Dean, Andrew Lightfoot, Susan Roomans